Teiko Bio
Salt Lake City, US · Founded 2020 · Delaware corporation · 6 known investors
Teiko provides multi-parameter cytometry services for clinical trials, including blood preservation kits (TokuKit), spectral and mass cytometry panels, and data analysis via its Dashboard platform. The company serves biotech firms and clinical trial sponsors conducting immunology studies globally.
Founders & leadership
Investors · 6
Reported raises · per SEC filings
Form D private placements▶$11.6MraisedOct 2021 · 40 investors · OtherRule 506(b)
▶$11.6MraisedOct 2021 · 40 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Ramji SrinivasanExecutive Officer, Director
- Matthew SpitzerDirector
- Victor WangDirector
- Offering amount
- $15.3M
- Amount sold
- $11.6M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Why DataDrivenInvestor invested in Teikoalexanderjarvis.com · 2024
- Why We Invested In Teiko -- Mapping Immune Profiles To Improve Clinical Outcomes — DataDrivenInvestordatadriveninvestor.com · 2021
- Teiko Global Equity & FX Fund SCSp, an unregulated alternative investment fund is created in Luxembourg as the official investment vehicle of Teiko Asset Management S.à r.l – Teiko Asset Managementteikoam.com
